MARLBOROUGH, Mass.--(BUSINESS WIRE)--May 22, 2006--Sepracor Inc. (Nasdaq: SEPR - News) today announced that data for LUNESTA(TM) brand eszopiclone for the treatment of insomnia will be presented at the annual meeting of the American Psychiatric Association in Toronto on May 23rd and 24th. The posters will be presented in the Toronto Convention Centre, North Level 300, Exhibit Hall B from 3:00 to 5:00 p.m. ET on both days.
